{"id":"vancomycin","brandName":"Vancocin","genericName":"vancomycin","companyId":"ani-pharmaceuticals","companyName":"ANI Pharmaceuticals","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase"},"administration":{"route":"Intravenous"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"6910 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"4706 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"4435 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"3955 reports"},{"date":"","signal":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS","source":"FDA FAERS","actionTaken":"2607 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"2435 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"2351 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"2321 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"2198 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"2140 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Nephrotoxicity","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hypokalemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"C. difficile colitis","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Hearing disorder","Kidney disease","Neutropenic disorder","Vancomycin poisoning"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Nephrotoxicity","drugRate":"5%","severity":"serious"},{"effect":"Ototoxicity","drugRate":"","severity":"serious"},{"effect":"Neutropenia","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious"},{"effect":"Red Man Syndrome","drugRate":"","severity":"serious"},{"effect":"Toxic epidermal necrolysis","drugRate":"","severity":"serious"},{"effect":"Drug reaction with eosinophilia and systemic symptoms","drugRate":"","severity":"serious"},{"effect":"Acute generalized exanthematous pustulosis","drugRate":"","severity":"serious"},{"effect":"Linear IgA bullous dermatosis","drugRate":"","severity":"serious"}]},"trials":["NCT01133600","NCT05697965","NCT01537666","NCT06030219","NCT01922011","NCT05632315","NCT02096536","NCT06504992","NCT04138706","NCT02137668","NCT03809260","NCT05079620","NCT03827447","NCT02384200","NCT01499277","NCT03137173","NCT07043673","NCT06384651","NCT03759041","NCT01196169","NCT01613092","NCT02461199","NCT04308473","NCT05077085","NCT06772675","NCT07435051","NCT02764359","NCT01431339","NCT03412500","NCT01701219","NCT02051595","NCT06729619","NCT02686645","NCT06702345","NCT00228410","NCT04991376","NCT02355938","NCT02400112","NCT01304771","NCT01241552","NCT03557008","NCT00529282","NCT00061633","NCT04132115","NCT04238091","NCT01458223","NCT07364435","NCT01040585","NCT07148960","NCT04825522"],"indications":{"approved":[{"name":"Bacterial endocarditis","diseaseId":"bacterial-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial septicemia","diseaseId":"bacterial-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Clostridium difficile diarrhea","diseaseId":"clostridium-difficile-diarrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diphtheroid Prosthetic Heart Valve Endocarditis","diseaseId":"diphtheroid-prosthetic-heart-valve-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of bone","diseaseId":"infection-of-bone","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infectious disorder of joint","diseaseId":"infectious-disorder-of-joint","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective endocarditis","diseaseId":"infective-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lower respiratory tract infection","diseaseId":"lower-respiratory-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal Group B Streptococcal Septicemia","diseaseId":"neonatal-group-b-streptococcal-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal pneumonia","diseaseId":"neonatal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteomyelitis due to Staphylococcus aureus","diseaseId":"osteomyelitis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prosthetic Heart Valve Endocarditis","diseaseId":"prosthetic-heart-valve-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pseudomembranous enterocolitis","diseaseId":"pseudomembranous-enterocolitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis of the newborn","diseaseId":"sepsis-of-the-newborn","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal Prosthetic Heart Valve Endocarditis","diseaseId":"staphylococcal-prosthetic-heart-valve-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal endocarditis","diseaseId":"staphylococcal-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal enterocolitis","diseaseId":"staphylococcal-enterocolitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal infectious disease","diseaseId":"staphylococcal-infectious-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pneumonia","diseaseId":"staphylococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal septicemia","diseaseId":"staphylococcal-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Epidermidis Skin and Skin Structure Infection","diseaseId":"staphylococcus-epidermidis-skin-and-skin-structure-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcal Endocarditis","diseaseId":"streptococcal-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Method of Use","number":"11517609","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"VANCOMYCIN","expiryDate":"2035-11-06"},{"type":"Formulation","number":"10188697","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"VANCOMYCIN","expiryDate":"2035-11-06"},{"type":"Formulation","number":"10039804","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"VANCOMYCIN","expiryDate":"2035-11-06"},{"type":"Formulation","number":"10849956","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"VANCOMYCIN","expiryDate":"2035-11-06"},{"type":"Formulation","number":"11000567","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"VANCOMYCIN","expiryDate":"2035-11-06"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT01133600","phase":"Phase 4","title":"Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens","status":"TERMINATED","sponsor":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","isPivotal":false,"enrollment":6,"indication":"Diabetic Foot","completionDate":"2012-08"},{"nctId":"NCT05697965","phase":"Phase 2","title":"TheUseofLocalVancomycinPowdertoPreventPeriprostheticJointInfectioninPrimaryTotalHipandKneeArthroplasty.ARandomizedControlledTrial.","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":174,"indication":"Arthroplasty Complications, Periprosthetic Fracture of Hip","completionDate":"2024-08"},{"nctId":"NCT01537666","phase":"Phase 1","title":"Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.","status":"COMPLETED","sponsor":"Savara Inc.","isPivotal":false,"enrollment":25,"indication":"Healthy, Cystic Fibrosis","completionDate":"2012-03"},{"nctId":"NCT06030219","phase":"Phase 1","title":"Microbiome Effect of Omadacycline on Healthy Volunteers","status":"COMPLETED","sponsor":"University of Houston","isPivotal":false,"enrollment":32,"indication":"Healthy Volunteers","completionDate":"2023-09-01"},{"nctId":"NCT01922011","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","isPivotal":true,"enrollment":149,"indication":"Acute Hematogenous Osteomyelitis","completionDate":"2016-12-20"},{"nctId":"NCT05632315","phase":"Phase 2","title":"A Phase II Randomized Trial to Evaluate the Impact of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products on Recipient and Environmental Colonization With Multidrug-Resistant O","status":"RECRUITING","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":150,"indication":"Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections","completionDate":"2026-05"},{"nctId":"NCT02096536","phase":"Phase 4","title":"Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Bin","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":120,"indication":"Neonatal Infection","completionDate":"2025-01"},{"nctId":"NCT06504992","phase":"Phase 4","title":"Powdered Intrawound Vancomycin in Open Fractures: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","isPivotal":false,"enrollment":350,"indication":"Open Fracture, Trauma","completionDate":"2029-09-01"},{"nctId":"NCT04138706","phase":"Phase 3","title":"Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","isPivotal":true,"enrollment":263,"indication":"Clostridium Difficile Infection","completionDate":"2024-11-22"},{"nctId":"NCT02137668","phase":"Phase 1","title":"The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin","status":"RECRUITING","sponsor":"Sacramento Pediatric Gastroenterology","isPivotal":false,"enrollment":200,"indication":"Primary Sclerosing Cholangitis, Biliary Atresia","completionDate":"2028-07"},{"nctId":"NCT03809260","phase":"NA","title":"A Clinical Trial for Analysis of Intestinal Microbiome Affecting Pharmacokinetics, Pharmacodynamics, and Safety of Metformin in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":20,"indication":"Human Microbiome","completionDate":"2019-02-28"},{"nctId":"NCT05079620","phase":"Phase 4","title":"Antibiotic Prophylaxis in Critically Ill Patients After Suspected Aspiration","status":"TERMINATED","sponsor":"UConn Health","isPivotal":false,"enrollment":5,"indication":"Aspiration, Aspiration Pneumonia","completionDate":"2024-04-12"},{"nctId":"NCT03827447","phase":"Phase 1","title":"Randomized Double Blind Placebo Controlled Trial for the Treatment of NAAT(+)/Toxin EIA(-) Clostridium Difficile","status":"COMPLETED","sponsor":"Medical College of Wisconsin","isPivotal":false,"enrollment":7,"indication":"Clostridium Difficile Infection","completionDate":"2021-06-30"},{"nctId":"NCT02384200","phase":"Phase 4","title":"The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1","status":"COMPLETED","sponsor":"University of California, San Diego","isPivotal":false,"enrollment":86,"indication":"Nephrolithiasis, Urinary Tract Infections","completionDate":"2019-06-01"},{"nctId":"NCT01499277","phase":"Phase 3","title":"A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":802,"indication":"Complicated Skin and Soft Tissue Infection","completionDate":"2015-01"},{"nctId":"NCT03137173","phase":"Phase 3","title":"A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin S","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","isPivotal":true,"enrollment":679,"indication":"Acute Bacterial Skin and Skin Structure Infections","completionDate":"2019-04-22"},{"nctId":"NCT07043673","phase":"N/A","title":"Plasma Concentrations of the Non-protein-bound Form of Vancomycin in Intensive Care","status":"COMPLETED","sponsor":"University Hospital, Rouen","isPivotal":false,"enrollment":77,"indication":"Plasma Concentration","completionDate":"2025-03-01"},{"nctId":"NCT06384651","phase":"Phase 4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","isPivotal":false,"enrollment":40,"indication":"Infections, Ankle Arthritis","completionDate":"2027-12"},{"nctId":"NCT03759041","phase":"Phase 2","title":"ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis","status":"TERMINATED","sponsor":"Seres Therapeutics, Inc.","isPivotal":false,"enrollment":203,"indication":"Ulcerative Colitis","completionDate":"2021-10-13"},{"nctId":"NCT01196169","phase":"Phase 4","title":"Daptomycin Use For Prophylaxis In Prosthetic Joint Surgery, A Randomized Prospective Study Comparing The Efficacy Of Daptomycin Versus Vancomycin For Peri-Operative Antibiotic Prophylaxis In MRSA Colo","status":"TERMINATED","sponsor":"Mountain Home Research & Education Corporation","isPivotal":false,"enrollment":28,"indication":"Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus","completionDate":"2014-03"},{"nctId":"NCT01613092","phase":"Phase 4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study","status":"COMPLETED","sponsor":"Population Health Research Institute","isPivotal":false,"enrollment":241,"indication":"Arrhythmia","completionDate":"2013-12"},{"nctId":"NCT02461199","phase":"N/A","title":"Prospective Observational Study of Fecal Microbiota Transplantation Used to Eradicate Gut-colonizing Multidrug-resistant Bacteria in Patients With Blood Disorders","status":"UNKNOWN","sponsor":"Medical University of Warsaw","isPivotal":false,"enrollment":50,"indication":"Blood Disorders","completionDate":"2017-09"},{"nctId":"NCT04308473","phase":"NA","title":"Analysis of MicroBial Metabolites After Eating Refined Food","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":46,"indication":"Dietary Habits","completionDate":"2026-07"},{"nctId":"NCT05077085","phase":"Phase 4","title":"New Treatment Strategy for Patients With Multiple Recurrent Clostridioides Difficile Infection With Bezlotoxumab as First Option","status":"WITHDRAWN","sponsor":"Leiden University Medical Center","isPivotal":false,"enrollment":0,"indication":"Clostridium Infections, Clostridioides Difficile","completionDate":"2024-12"},{"nctId":"NCT06772675","phase":"NA","title":"Implementing Vancomycin Reducing Practices (VRP) in Preterm Infants","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","isPivotal":false,"enrollment":13,"indication":"Antibiotic Stewardship, Neonatal Sepsis, Late-Onset","completionDate":"2027-09"},{"nctId":"NCT07435051","phase":"Phase 3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Bombined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":true,"enrollment":280,"indication":"Osteomyelitis (Refractory)","completionDate":"2030-12-31"},{"nctId":"NCT02764359","phase":"NA","title":"Single-Center Prospective Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens","status":"UNKNOWN","sponsor":"CAMC Health System","isPivotal":false,"enrollment":128,"indication":"Infection, Sepsis","completionDate":"2021-01-22"},{"nctId":"NCT01431339","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin a","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","isPivotal":true,"enrollment":739,"indication":"Abscess, Wound Infection","completionDate":"2012-12"},{"nctId":"NCT03412500","phase":"Phase 4","title":"A Comparative Efficacy Study of Vancomycin Dosage Adjustment by Equation-based Method and Vancomycin Trough Concentration Method for Treatment of Infections Caused by Methicillin Resistant Staphylococ","status":"UNKNOWN","sponsor":"Pinyo Rattanaumpawan","isPivotal":false,"enrollment":114,"indication":"Methicillin-Resistant Staphylococcus Aureus","completionDate":"2018-09"},{"nctId":"NCT01701219","phase":"Phase 4","title":"A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureu","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":56,"indication":"Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia","completionDate":"2014-07"},{"nctId":"NCT02051595","phase":"EARLY/Phase 1","title":"The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery","status":"COMPLETED","sponsor":"University of Florida","isPivotal":false,"enrollment":25,"indication":"Infection","completionDate":"2015-04"},{"nctId":"NCT06729619","phase":"N/A","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","isPivotal":false,"enrollment":200,"indication":"Intracranial Infection, Central Infection","completionDate":"2027-12-31"},{"nctId":"NCT02686645","phase":"Phase 2","title":"Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection","status":"UNKNOWN","sponsor":"Queen Elizabeth II Health Sciences Centre","isPivotal":true,"enrollment":50,"indication":"Clostridium Difficile Infection","completionDate":"2021-12"},{"nctId":"NCT06702345","phase":"NA","title":"Establishing a Clostridioides Difficile Controlled Human Infection Model","status":"NOT_YET_RECRUITING","sponsor":"Leiden University Medical Center","isPivotal":false,"enrollment":60,"indication":"C. Difficile, C. Difficile Infection","completionDate":"2026-12-31"},{"nctId":"NCT00228410","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospital","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":true,"enrollment":503,"indication":"Skin Diseases, Infectious","completionDate":"2003-12"},{"nctId":"NCT04991376","phase":"N/A","title":"Differentiation of Acute Kidney Injury in Sepsis and Due to Nephrotoxic Antibiotic Treatment With Vancomycin and Gentamicin Based on Measurements of Specific miRNAs","status":"COMPLETED","sponsor":"University Hospital Ostrava","isPivotal":false,"enrollment":53,"indication":"Sepsis, Septic Shock","completionDate":"2022-12-01"},{"nctId":"NCT02355938","phase":"Phase 4","title":"Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection","status":"TERMINATED","sponsor":"Baylor College of Medicine","isPivotal":false,"enrollment":12,"indication":"Clostridium Difficile, Spinal Cord Injury","completionDate":"2016-10"},{"nctId":"NCT02400112","phase":"Phase 4","title":"Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures","status":"TERMINATED","sponsor":"University of Tennessee","isPivotal":false,"enrollment":11,"indication":"Fractures, Open, Surgical Wound Infection","completionDate":"2018-10"},{"nctId":"NCT01304771","phase":"Phase 1","title":"A Phase I Trial of the Safety and Efficacy of Adjuvant AKSB (Agri-King Synbiotic) Synbiotic in Patients 65 Years of Age and Older Receiving the Influenza Vaccine","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":22,"indication":"Influenza","completionDate":"2011-04"},{"nctId":"NCT01241552","phase":"Phase 3","title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Dif","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1452,"indication":"Clostridium Difficile Infection","completionDate":"2014-12-09"},{"nctId":"NCT03557008","phase":"Phase 4","title":"Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":37,"indication":"Rabies Human","completionDate":"2022-06-02"},{"nctId":"NCT00529282","phase":"Phase 3","title":"Multicenter, Randomized, Double-Blind Study of Ceftobiprole Versus Comparators in the Treatment of Patients With Fever and Neutropenia","status":"TERMINATED","sponsor":"Basilea Pharmaceutica","isPivotal":true,"enrollment":2,"indication":"Fever, Neutropenia","completionDate":"2008-01"},{"nctId":"NCT00061633","phase":"Phase 2","title":"A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive ","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","isPivotal":false,"enrollment":169,"indication":"Infections, Gram-Positive Bacterial, Abscess","completionDate":"2004-01"},{"nctId":"NCT04132115","phase":"N/A","title":"Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","isPivotal":false,"enrollment":104,"indication":"Therapeutic Drug Monitoring, Subarachnoid Hemorrhage","completionDate":"2021-10"},{"nctId":"NCT04238091","phase":"Phase 2","title":"Open Label Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata","status":"WITHDRAWN","sponsor":"Lindsey Bordone","isPivotal":false,"enrollment":0,"indication":"Alopecia Areata, Alopecia Totalis","completionDate":"2022-03-02"},{"nctId":"NCT01458223","phase":"Phase 4","title":"The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain","status":"COMPLETED","sponsor":"The London Spine Centre","isPivotal":false,"enrollment":645,"indication":"Postoperative Infection","completionDate":"2018-08"},{"nctId":"NCT07364435","phase":"NA","title":"The Effect of Two Different Bed Bathing Methods on Vancomycin-Resistant Enterococcus Colonization in Intensive Care Patients: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Özkan Kasap","isPivotal":false,"enrollment":210,"indication":"Vancomycin-Resistant Enterococcus","completionDate":"2025-08-01"},{"nctId":"NCT01040585","phase":"N/A","title":"Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America","status":"WITHDRAWN","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Ventilator Acquired Pneumonia","completionDate":"2011-03"},{"nctId":"NCT07148960","phase":"Phase 4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (SABEDTIO) Clinical Trial","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","isPivotal":false,"enrollment":300,"indication":"Staphylococcus Aureus Bacteremia","completionDate":"2027-07"},{"nctId":"NCT04825522","phase":"Phase 4","title":"The Effect of Intrawound Vancomycin Powder in Spine Surgery: A Prospective Randomized Controlled Trial","status":"RECRUITING","sponsor":"Windsor-Essex Compassionate Care Community","isPivotal":false,"enrollment":1643,"indication":"Spine Disease","completionDate":"2028-12-01"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.4848/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$542","description":"VANCOMYCIN HCL 125 MG CAPSULE","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-28T00:00:00.000Z","mah":"XELLIA PHARMS APS","brand_name_local":null,"application_number":"ANDA204125"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-10T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":null,"application_number":"NDA209481"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-08-19T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA205694"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-09-20T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA204107"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-11-12T00:00:00.000Z","mah":"PLANO PHARMS","brand_name_local":null,"application_number":"ANDA201048"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"11517609","territory":"US","patent_type":"Method of Use","expiry_date":"2035-11-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10188697","territory":"US","patent_type":"Formulation","expiry_date":"2035-11-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10039804","territory":"US","patent_type":"Formulation","expiry_date":"2035-11-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10849956","territory":"US","patent_type":"Formulation","expiry_date":"2035-11-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11000567","territory":"US","patent_type":"Formulation","expiry_date":"2035-11-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":6,"withResults":3},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vancomycin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:30:05.230289+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:30:05.230217+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:30:10.940046+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:30:04.268602+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vancomycin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:30:11.306698+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:02.429355+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:02.429377+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:30:26.647839+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Peptidoglycan inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:12.449842+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL262777/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:12.097518+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA205694","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:02.429382+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:29.248215+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL262777"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}